Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Most Problematic Leukemia Drugs Recalled (China)

This article was originally published in PharmAsia News

Executive Summary

Chinese officials announced they have successfully recalled the majority of two-types of leukemia drugs. Methotrexate and cytarabin hydrochloride, both manufactured by Shanghai Hualian Pharmaceutical, Co. were recalled by Chinese health authorities as of Sept. 5 after reports of unusual side-effects. The Chinese Ministry of Health and the State Food and Drug Administration have since been working with Shanghai Hualian to remove the two drugs from the market and trace the cause of the side-effects. As of Sept. 14, officials announced they have found the source of the mysterious symptoms, which included trouble walking and urine retention. According to reports, the side-effects were the result of the accidental addition of vincristine sulfate, another anti-cancer treatment, into several batches of the leukemia treatments. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066526

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel